Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP

REFERENCES

• Hiddemann W, Unterhalt M, Herrmann R, Woltjen HH, Kreuser ED, Trumper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, et al. Mantle-cell lymphomas have more widespread disease and a slower response compared with follicle-centre lymphomas: results of a prospective compara-tive analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998;16:1922–1930.
   Google Scholar
• Meusers P, Engelhard M, Bartels H, Binder T, Fulle HH, Gorg K, Gunzer U, Havemann K, Kayser W, Konig E. Multicentre randomised therapeutic trial for advanced cen-trocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989;7:365— 380.
   Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   Google Scholar
• Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Chin Oncol 2002;20:1288–1294.
   Google Scholar
• Tam C, Wolf MM, Januszewicz EH, Prince HM, Westerman DA, Seymour JF. Fludarabine and cyclophosphamide using a 3-day attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer 2004;101:2181–2189.
   Google Scholar
• Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.Leuk Lymphoma 2001;42:1015–1022.
   Google Scholar
• Keating M, Manshouri T, O'Brien S, Wierda W, Kantarjian H, Washington L, Lerner S, Albitar M. A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia (CLL). Blood 2002;100\(Supp1.1):205a (abstract #771).
   Google Scholar
• Forstpointer R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pon C, Hartmann F, Rothmann F, Rohrberg R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) signifi-cantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas — results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2004;104:3064 — 3071.
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al. Report of an international workshop to standardise response criteria for non-Hodgkin's lymphomas. J Chin Oncol 1999;17:1244–1253.
   Google Scholar
• Velders GA, Kluin-Nelemans JC, De Boer CJ, Hermans J, Noordijk EM, Schuuring E, Kramer MH, Van Deijk WA, Rahder JB, Kluin PM, Van Krieken JH. Mantle-cell lympho-ma: a population-based clinical study. J Chin Oncol 1996;14:1269–1274.
   Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Chin Oncol 1998;16:3803–3809.
   Google Scholar
• Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C, Guilhot F, Vose JM, van Biesen K, Rizzo JD, et al. Outcome of autologous transplanta-tion for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003;120:793 — 800.
   Google Scholar
• Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, Vaughan Hudson B, Pittaluga S, Anderson L, Linch DC. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997;99: 842— 847.
   Google Scholar
• Morgan SJ, Seymour JF, Grigg AP, Matthews JP, Prince HM, Wolf MM, Januszewicz EH. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproli-ferative disorders previously treated with fludarabine. Leukemia 2004;18:1034— 1038.
   Google Scholar
• Hiddemann W, Forstpointer R, Kneba M, Schmitz N, Schmits R, Metzner B, Reiser M, Lengfelder E, Woermann B, Harder H, et al. The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: results of two prospective randomised studies of the German Low Grade Lymphoma Study Group (GLSG). Blood 2004;104\(Suppl. 1):50a (ab-stract (161).
   Google Scholar